1. Home
  2. MITQ vs AKTX Comparison

MITQ vs AKTX Comparison

Compare MITQ & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.61

Market Cap

5.9M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$16.64

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
AKTX
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
6.5M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
MITQ
AKTX
Price
$0.61
$16.64
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
90.0K
1.4M
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$58.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.12
52 Week High
$1.66
$29.32

Technical Indicators

Market Signals
Indicator
MITQ
AKTX
Relative Strength Index (RSI) 47.99 64.60
Support Level $0.57 $0.69
Resistance Level $0.64 N/A
Average True Range (ATR) 0.04 3.78
MACD -0.00 1.53
Stochastic Oscillator 53.48 49.90

Price Performance

Historical Comparison
MITQ
AKTX

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: